Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

ALAMEDA, Calif.–(BUSINESS WIRE)– #CRISPR–Data on Scribe’s X-Editor technologies validates the high activity, specificity and deliverability achievable through CRISPR by Design™


ADVERTISEMENT — Advertise With Biotech Networks